BOSTON — A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.
These new findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and published in today’s on-line issue of The Journal of Clinical Investigation (JCI), identify a novel strategy for preventing thrombosis, and help pave the way for clinical testing of this popular flavonoid as a therapy for the prevention and treatment of stroke and heart attack, as well as deep venous thrombosis (DVT) and pulmonary embolism.
“It’s not always fully appreciated that the majority of Americans will die as the result of a blood clot in either their heart or their brain,” says senior author Robert Flaumenhaft, MD, PhD, an investigator in the Division of Hemostasis andThrombosis at BIDMC and Associate Professor of Medicine at Harvard Medical School. “Approximately half of all morbidity and mortality in the United States can be attributed to heart attack or stroke.”
The study focused on protein disulfide isomerase (PDI) which is found in all cells. Investigators in BIDMC’s Division of Hemostasis and Thrombosis had previously shown that PDI is rapidly secreted from both platelets and endothelial cells during thrombosis, when a clot forms in a blood vessel, and that inhibition of PDI could block thrombosis in a mouse model.
“This was a transformative and unanticipated finding because it identified, for the first time, that PDI is secreted from cells in a live animal and is a potential target for preventing thrombosis,” says Flaumenhaft. However, because intracellular PDI is necessary for the proper synthesis of proteins, the scientists had to identify a specific compound that could block the thrombosis-causing extracellular PDI – without inhibiting the intracellular PDI.
They began by conducting a high-throughput screen of a wide array of compounds to identify PDI inhibitors. Among the more than 5,000 compounds that were screened, quercetin-3-rutinoside (rutin) emerged as the most potent agent. “Rutin was essentially the champion compound,” says Flaumenhaft.
A bioflavonoid that is naturally found in many fruits, vegetables and teas including onions, apples and citrus fruits, rutin is also sold as an herbal supplement, having received a special designation for safety from the U.S. Food and Drug Administration (FDA). Surprisingly, studies of the rutin molecule demonstrated that the same part of the molecule that provides rutin with its ability to inhibit PDI also prevents the compound from entering cells. “That finding explained how this compound can be both a potent inhibitor of PDI and a safe food supplement,” says Flaumenhaft. “Our next questions were, ‘Is this compound anti-thrombotic? Can it prevent blood clots?’”
The team went on to test rutin in a mouse model of thrombosis. Because they knew that humans would be taking rutin in pill form, they included studies in which the compound was administered orally and determined that it successfully retained its anti-thrombotic properties when it was metabolized following oral ingestion.
“Rutin proved to be the most potently anti-thrombotic compound that we ever tested in this model,” says Flaumenhaft. Of particular note, rutin was shown to inhibit both platelet accumulation and fibrin generation during thrombus formation. “Clots occur in both arteries and in veins,” explains Flaumenhaft. “Clots in arteries are platelet-rich, while those in veins are fibrin-rich. This discovery suggests that a single agent can treat and prevent both types of clots.”
Even with the use of existing anti-clotting therapies, such as aspirin, clopidogrel (Plavix) and warfarin (Coumadin), each year there are approximately 400,000 recurrent episodes among patients who previously experienced a stroke or heart attack, says Flaumenhaft.
“A safe and inexpensive drug that could reduce recurrent clots could help save thousands of lives,” he adds. “These pre-clinical trials provide proof-of-principle that PDI is an important therapeutic target for anti-thrombotic therapy, and because the FDA has already established that rutin is safe, we are poised to expeditiously test this idea in a clinical trial, without the time and expense required to establish the safety of a new drug.”
The original research that identified this mechanism as well as the identification of PDI as a drug target of rutin was supported primarily by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) and also from the American Heart Association. Additional support came from the European Hematology Association-American Society of Hematology and the Foundation for Women’s Wellness.
Study coauthors include BIDMC investigators Reema Jasuja (first author), Freda H. Passam, Daniel R. Kennedy, Sarah H. Kim, Lotte van Hessem, Lin Lin, Sheryl R. Bowley, Sucharit S. Joshi, James R. Dilks, Bruce Furie and Barbara C. Furie, all of the Division of Hemostasis and Thrombosis.
BIDMC Contact: Bonnie Prescott
Phone: (617) 667-7306